A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-02-16
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-06 (study day 185); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 214); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 236); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 244); relationship: Y
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-22 (study day 262); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 318); relationship: Y
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-16 (study day 377); relationship: not assessed
Data queries
No data queries.